Hot Clean Energy Stocks To Buy For 2014

I went out on a limb last week, and now it's time to see how that decision played out.

I predicted that Clean Energy Fuels (NASDAQ: CLNE  ) would close higher on the week. The provider of natural gas fueling solutions for transportation has been posting narrowing losses, and Wall Street was eyeing a 35% surge in revenue. The company was a solid report. Revenue came in a little light, but bottom-line results improved nicely. Shares of Clean Energy Fuels moved slightly higher on the week. I was right. I predicted that the tech-heavy Nasdaq would outperform the Dow Jones Industrial Average. (DJINDICES: ^DJI  ) . This has been a tricky call lately, so how did it play out this time? Well, the market had a strong run this week, fueled be encouraging economic news. Secondary stocks led the way, with the Nasdaq soaring 1.7% on the week. The Dow managed to close just 1% higher. I was right. My final call was for Compass Diversified Holdings (NYSE: CODI  ) to beat Wall Street's quarterly profit target. The investor in several middle-market companies has been posting blowout quarterly results over the past year, and I was banking on seeing the trend continue. Analysts were looking for a profit of $0.36 a share during the quarter, but Compass Diversified failed to beat the prognosticators. I was wrong.

Two out of three? I'll take it. That makes me eight of nine over the past three weeks.

Hot Income Stocks To Invest In 2015: Dendreon Corporation(DNDN)

Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of therapeutics to enhance cancer treatment options for patients. The company offers active cellular immunotherapy and small molecule product candidates to treat various cancers. Its product candidates comprise Provenge (sipuleucel-T), an active cellular immunotherapy for the treatment of metastatic, castrate-resistant prostate cancer; DN24-02, an investigational active immunotherapy for the treatment of patients with bladder, breast, ovarian, and other solid tumors expressing HER2/neu; and TRPM8, a small molecule agonist to transient receptor potential ion channel, for multiple cancers. The company also has a range of products in preclinical studies, which include Carcinoembryonic antigen for the treatment of lung, colon, and breast cancer; and Carbonic AnhydraseIX for the treatment of kidney cancer. Dendreon Corporation was founded in 1992 and is headquartered in S eattle, Washington.

Advisors' Opinion:

• [By Johanna Bennett]

  Once, one of the hottest biotech stocks around, Dendreon (DNDN) has become a cautionary tale, warning investors what can happen when a cutting-edge�drug turns into a dud.

  Now at less than $3 a share, the stock had traded as high as $54 in 2010 as excitement buzzed over the�experimental prostate cancer vaccine Provenge. Initially, Wall Street expected peak sales of $3 billion to $4 billion. But insurers balked at the�hefty price tag for Provenge, and now, three years after it�won FDA approval, analysts see annual sales at roughly $300 million.

  Disappointing sales are just one reason Deutsche Bank has joined the�bearish�voices surrounding this drug maker.�Today, analyst Robyn Karnauskas downgraded Dendreon�to a Sell and cut the�price target to $1, warning that even if the company�can significantly reduce�costs and drastically restructures, its�spending may still outpace revenue growth in the short-term. Karnauskas believes Dendreon may have to refinance its debt, negatively impacting shareholders.

  Earlier this month, the company�posted a bigger-than-expected second-quarter loss as Provenge sales fell compared to last year. A restructuring plan was�unveiled in late July, though�analysts say it isn’t enough without revenue growth.�Today, Deutsche Bank’s Karnauskas writes:�

  …By our math, even with $165M in cost cuts, the co will have to grow current sales from $300M to $525M over next 7 years to support current share price. 2Q13 sales were $73M and DTC campaign does not seem to have a lot of effect to offset impact from competition so that the company could reach profitability in 4Q13. While they note that they plan to cut costs, we are concerned it may be too late. Revenue growth is not occurring quick enough; we note 1Q13 yoy growth was guided and in 2Q13 they noted this was unlikely to occur going fwd. The co�� inability to guide growth & provide visibility makes it difficult for us to see sales a

• [By Bryan Murphy]

  There's no doubt about it - the "in" thing to do with Dendreon Corporation (NASDAQ:DNDN) lately has been to bash it. The company's one and only drug, Provenge, failed to meet its sales estimates last quarter. And worse, DNDN was forced to announce 2013's top line wouldn't be as strong as first expected. Between that lowered guidance and growing fears that Provenge may not be nearly as marketable as first assumed, the stock plunged 26% on Friday, and has since widened that loss to 30%.

• [By Sean Williams]

  In order to do their best to conserve cash leading up into the full implementation of the bill, I wouldn't be surprised to see insurers denying or declining to pick up the tab on what they deem overpriced procedures. Not to pick on Intuitive Surgical again, but the company did mention, "a trend by payers toward encouraging conservative management and treatment in outpatient settings." Another potential victim here is Dendreon (NASDAQ: DNDN  ) , whose cellular immunotherapy known as Provenge that's used to treat advanced prostate cancer costs $93,000 annually. By comparison, Johnson & Johnson's�Zytiga costs just $5,500 per month ($66,000 annually) and would be the better cost-effective choice for insurers, potentially leaving Provenge out in the cold.

• [By WALLSTCHEATSHEET]

  Dendreon is suffering from lower product sales, which is due to increased competition. Costs are too high, and the company culture is awful. On the other hand, Dendreon narrowed its loss in Q1 on a year-over-year basis, and it expects conditions to improve. While that�� an expected statement from any company that�� performing poorly, and while Dendreon currently relies heavily on Provenge,�Dendreon isn�� a one-trick pony.�It still has several other drugs in the pipeline. It should also be noted that Dendreon has been on the brink of disaster many times throughout its history. It has clawed its way back to life in every instance. Perhaps it has nine lives. If that�� the case, it has used up four of them so far.

Hot Clean Energy Stocks To Buy For 2014: Renishaw PLC (RSW)

Renishaw plc is a metrology company. The Company is engaged in the design, manufacture and sale of advanced precision metrology and inspection equipment together with products for the healthcare sector, including Raman spectroscopy systems, dental systems, molecular diagnostic equipment and neurosurgical products. The Company operates in two segments: metrology and healthcare products. The Company�� metrology segment product include Machine Tool Probe Systems, Co-ordinate Measuring Machine (CMM) products, large scale metrology, fixtures, materials research, styli for probe systems, performance testing products, gauging and position encoders. Its healthcare products include Dental Scanners, Raman Microscopes, Dental CAD Software, Neurosurgical robot, Structural and Chemical Analyser, In situ monitors and Neurosurgical Implantables. Advisors' Opinion:

• [By Inyoung Hwang]

  Renishaw Plc (RSW) tumbled 5.7 percent to 1,580 pence, its lowest price since Aug. 7. The maker of precision tools said revenue for the quarter ended in September fell to 79 million pounds from 95.9 million pounds in the year-ago period.

Hot Clean Energy Stocks To Buy For 2014: Vivendi SA (VIVHY.PK)

Vivendi SA (Vivendi), incorporated on December 18, 1987, is a communications and entertainment company. As of December 31, 2009, the Company had six business segments: Activision Blizzard, Universal Music Group, SFR, Maroc Telecom Group, GVT (Holding) S.A. (GVT) and Canal+ Group. Activision Blizzard develops, publishes and distributes interactive entertainment software, online or on other media (such as console and personal computer (PC)). Universal Music Group is engaged in the sale of recorded music (physical and digital media), exploitation of music publishing rights, as well as artist services and merchandising. SFR is engaged in the phone services (mobile, broadband Internet and fixed) in France. Maroc Telecom Group is a telecommunication operator (mobile, fixed and Internet) in Africa, principally in Morocco, as well as in Mauritania, Burkina Faso, Gabon and Mali. GVT is a Brazilian fixed and broadband operator. Canal+ Group is engaged in publishing and distribution of pay-television mainly in France, in both analog and digital (terrestrially, via satellite or ADSL), as well as film production in Europe. In July 2013, Vivendi SA and Universal Music Group announced the completion of the sale of Parlophone Label Group to Warner Music Group Corp.

On November 13, 2009, Vivendi acquired an aggregate of 29.9% of GVT�� outstanding voting shares from Swarth Investments LLC, Swarth Investments Holdings LLC and Global Village Telecom (Holland) BV. In addition, Vivendi acquired from third parties an additional 8% interest in GVT's outstanding shares. On December 28, 2009, Canal+ Group, Vivendi�� subsidiary, acquired TF1�� 9.9% interest in the capital of Canal+ France. On July 31, 2009, Maroc Telecom acquired 51% controlling interest in Sotelma. On August 27, 2009, CID, a company 40% owned by SFR and 60% by other financial investors, acquired the 62% interest in 5 sur 5.

Advisors' Opinion:

• [By Eric Rodawig]

  Activision Blizzard (ATVI) is the world's largest and most successful video game developer, and is majority owned (61%) by French telecom and media conglomerate Vivendi (VIVHY.PK). Vivendi has been undergoing a massive strategic review with the intent to reduce debt and unlock the value of its assets that has fueled speculation surrounding ATVI. In conjunction with this, ATVI CFO Dennis Durkin announced on the 4Q12 earnings call

• [By Mike Arnold]

  I normally don't look at charts much, but comparing Orange to its competitors in the French telecommunications market is quite fascinating. As one can see, incumbents Bouygues (BOUYF.PK) and Vivendi (VIVHY.PK) (owner of SFR) saw similar price declines. The market, on the other hand, rapidly bid up the price of new entrant Iliad SA (ILIAF.PK), as a result of forecasts for Iliad to capture significant mobile market share (which it did, around 10%). The wide divergence in price relative to changes in underlying value favor going long the incumbents, including Orange. Because this time it's different.

Hot Clean Energy Stocks To Buy For 2014: Campus Crest Communities Inc (CCG)

Campus Crest Communities, Inc., incorporated on March 1, 2010, is a self-managed, self-administered and vertically-integrated developer, builder, owner and manager of purpose-built student housing properties in the United States. The Company operates in two segments: student housing operations and development, construction and management services. It owns the general partner interest and owns limited partner interests in Campus Crest Communities Operating Partnership, LP (the Operating Partnership). It holds substantially all of its assets and conducts substantially all of its business, through the Operating Partnership. As of December 31, 2010, it owned interests in 27 operating student housing properties containing approximately 5,048 apartment units and 13,580 beds. Twenty-one of its properties, containing approximately 3,920 apartment units and 10,528 beds, are wholly owned. On October 19, 2010, it acquired the remaining interest in Campus Crest at San Marcos, LLC, which owns The Grove at San Marcos, from HSRE. In January 2012, the Company acquired 50.1% interests in The Grove. On December 27, 2013, the Company closed its sale of four wholly owned student housing properties. In January 2014, Campus Crest Communities Inc and Beaumont Partners joint venture partnership acquired the 488-room, 22-story Holiday Inn Midtown in Montreal, Quebec.

As of December 31, 2010, the average occupancy for its 27 properties was approximately 88%. Its properties are primarily located in medium-sized college and university markets. As of December 31, 2010, the Company were party to one joint venture arrangement with HSRE, in which it owns a 49.9% interest.

Student Housing Operations

The Company�� student housing operations are consisted of rental and other service revenues, such as application fees, pet fees and late payment fees. In August 2010, the Company opened three additional properties that were owned by the same real estate venture.

Development, Construc! tion and Management Services

The Company provides development and construction services to unconsolidated joint ventures in which it has an ownership interest. The Company acts as a general contractor on all of its construction projects. In addition to its wholly owned properties, all of which are managed by the Company, it also provides management services to uncombined joint ventures in which, it has an ownership interest.

Advisors' Opinion:

• [By Lawrence Meyers]

  Campus Crest Communities (CCG) operates 33 student housing properties comprising 6,324 apartment units under its ��rove��brand name. It�� a REIT, so it distributes a minimum of 90% of taxable income as a common dividend of roughly 6%, which may even attract other investors. Campus Crest carries $225 million in debt and services it at a rate of about 5%. The company came into its own in 2012, as it reported solid EBITDA of $16.5 million and a profit after debt service and preferred stock payments, which it just started that year.

• [By Jonas Elmerraji]

  2013 is panning out to be a rough year for Campus Crest Communities (CCG) -- shares of the small-cap student housing REIT have slid 12.7% since the calendar flipped over to January. While that sounds bad enough as it is, it's actually 31% underperformance vs. the S&P 500. And a quick glance at the chart makes it pretty clear to see why.

  CCG is stuck in a textbook downtrend right now, bouncing between trendline resisatnce to the upside and a parallel support level below. You don't have to be an expert technical analyst to figure out where CCG's high probability price action is from here; it's down. Trendline resistance has acted as a ceiling for shares on the last four tests in 2013 – and with shares hitting their head on that resistance level this week, now's the optimal time to sell (or short) this REIT.

  If you're looking for an opportunity to buy CCG, you could be in for a long wait. But the 50-day moving average has been a pretty good proxy for resistance since the start of the summer. I'd recommend waiting for that line to get broken before even thinking about doing anything but selling this stock. Until then, it's toxic.

Hot Clean Energy Stocks To Buy For 2014: Oppenheimer Holdings Inc.(OPY)

Oppenheimer Holdings Inc., through its subsidiaries, operates as a middle-market investment bank and full service broker-dealer. It offers full-service brokerage services covering various investment alternatives, such as exchange-traded and over-the-counter corporate equity and debt securities, money market instruments, exchange-traded options and futures contracts, municipal bonds, mutual funds, and unit investment trusts. The company also provides financial and wealth planning services; margin lending; securities lending; and online equity investing and discount brokerage services. In addition, it offers asset management services for equity, fixed income, large-cap balanced, and alternative investments offered through vehicles, such as privately managed accounts, and retail and institutional separate accounts. Further, the company provides strategic advisory services and capital markets products; institutional equity sales and trading; equity research; equity options and derivatives; convertible bonds; and event driven sales and trading services. Additionally, it trades in non-investment grade public and private debt securities, mortgage-backed securities, sovereign and corporate debt, and distressed securities; provides fixed income research, public finance, and municipal trading services; and is involved in proprietary trading and investment activities. The company also participates in loan syndications and operates as underwriting agent in financing transactions; trades syndicated corporate loans in the secondary market; offers various trust services; and provides mortgage services to developers of commercial properties. It serves high-net-worth individuals and families, corporate executives, small and mid-sized businesses, endowments and foundations, and institutions in the United States, Europe, the Middle East, Asia, and South America. The company was founded in 1977 and is headquartered in New York, New York.

Advisors' Opinion:

• [By Hilary Kramer]

  With this news, some Wall Street firms finally ��albeit a bit late ��jumped on the ICPT bandwagon.� Citigroup (C) raised its target to $400, stating that its market cap (at the time $5.4 billion) didn�� reach the opportunity for these liver disease treatments.� They estimated that the OCA could exceed a $5 billion sales level.� Oppenheimer (OPY) also raised its target to $360 while Bank of America/Merrill’s (BAC) target is set at $872, the only one not yet exceeded with the most recent move.

Hot Clean Energy Stocks To Buy For 2014: Danske Bank A/S (DANSKE)

Danske Bank A/S (the Bank) is a Denmark-based bank. Its operations are divided into five business segments: Banking Activities caters to personal and business customers, comprising finance centers, mortgage finance operations and real estate agency operations, as well as property finance operations; Danske Markets and Treasury is responsible for the Bank�� activities in the financial markets, such as trading in fixed income, foreign exchange, equities and interest-bearing securities, as well as equity portfolios, among others; Danske Capital is engaged in the development and marketing of wealth management products and services; Danica Pension encompasses the Bank�� activities in the life insurance and pensions market; Other Activities encompasses the Bank�� real estate activities and support functions, as well as the elimination of returns on own shares and bonds. Is operational in 15 countries, with emphasis on the Nordic region. Advisors' Opinion:

• [By Namitha Jagadeesh]

  Kabel Deutschland Holding AG rose to a record after getting an offer from Liberty Global Plc. Aveva Group Plc (AVV) jumped 5.4 percent as Citigroup Inc. upgraded the shares. Danske Bank A/S (DANSKE) dropped 6.1 percent after Denmark�� financial regulator ordered it to increase its risk-weighted assets. Royal Imtech NV fell to the lowest price since 2004 after posting a first-quarter loss on costs relating to a fraud investigation.